Cogent Biosciences, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 7, 2023. Cogent is a clinical-stage biotechnology company developing precision therapies. Its lead candidate is bezuclastinib, a KIT inhibitor being studied in systemic mastocytosis and gastrointestinal stromal tumors (GIST). The company has no approved products and has not generated product-sales revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $50.1 million | $29.9 million | $125.0 million | $84.9 million |
| General and administrative expense | $9.5 million | $6.9 million | $24.9 million | $19.2 million |
| Net loss | $55.4 million | $35.1 million | $138.0 million | $100.6 million |
| Basic and diluted loss per share | $0.64 | $0.50 | $1.79 | $1.84 |
| Cash used in operating activities | Not separately stated | Not separately stated | $109.6 million | $89.2 million |
At September 30, 2023, cash and cash equivalents were $86.8 million and marketable securities were $226.0 million, totaling $312.8 million. Total assets were $355.4 million; total liabilities were $52.5 million, including $19.2 million of operating lease liabilities. No debt balance is reported. Current assets were $286.0 million and current liabilities $34.7 million. Stockholders’ equity was $302.9 million. Gross and operating margins are not meaningful because the company reported no revenue.
Management expects available cash, cash equivalents and marketable securities to fund operating expenses and capital requirements into 2026, while cautioning that estimates rely on assumptions and capital may be exhausted sooner. The financial-statement note separately states funding is expected to cover at least 12 months from issuance.
Material changes and notable items
- Q3 operating expenses increased $22.8 million year over year; nine-month expenses increased $45.8 million. Management attributed the increases mainly to clinical and manufacturing work on bezuclastinib, expanded research programs, higher headcount and stock-based compensation.
- Q3 net loss widened by $20.3 million year over year. For the first nine months, net loss widened by $37.4 million, despite higher interest income and a $1.7 million non-cash gain from reducing the contingent value right (CVR) liability to zero.
- Operating cash use increased $20.3 million year over year for the first nine months. Investing cash use was $108.3 million, largely reflecting purchases of marketable securities, partly offset by maturities and sales.
- A June 2023 public offering raised approximately $161.8 million net and issued 14.375 million common shares. Common shares outstanding rose to 86.1 million from 69.9 million at December 31, 2022. Including convertible preferred stock and remaining pre-funded warrants, the company reported 105.3 million shares on an as-converted basis at September 30.
- Interest income rose to $9.2 million for the first nine months from $1.9 million, reflecting higher average rates and invested balances. Sublease income declined after the former headquarters lease and sublease expired in April 2023.
Outlook, programs and risks
- Management expects research and development expenses and capital needs to increase as clinical studies advance. It anticipates continued operating losses and expects to need additional funding; possible sources include equity or debt financing, collaborations, licensing and other arrangements. Financing may dilute shareholders or require restrictions or concessions of rights.
- SUMMIT Part 1 in non-advanced systemic mastocytosis completed enrollment in Q3 at 54 patients. The company planned initial Part 1a data for December 2023, further Part 1 data in Q1 2024, and SUMMIT Part 2 initiation in the first half of 2024.
- APEX Part 2 enrollment was on track to complete by year-end 2024. The Phase 3 portion of PEAK was also on track to complete enrollment by year-end 2024. Updated PEAK lead-in results presented in November 2023 included a 33% confirmed response rate in a subset of second-line GIST patients; median duration of therapy was ongoing at more than 14 months. These are clinical findings, not evidence of approval or commercial revenue.
- The company selected FGFR2 candidate CGT4859 and expected to initiate a clinical trial in 2024; it expected to announce an ErbB2 candidate in 2024. These programs remained preclinical or in IND-enabling work.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; regulatory approval; manufacturing and supply; intellectual-property protection; competition; and access to additional capital. The filing reported no material change to the risk factors in the 2022 Form 10-K, no material legal proceedings, and effective disclosure controls as of September 30, 2023.
Investor verification priorities
- Track cash burn against the stated runway into 2026, including trial, manufacturing and research spending, and whether additional financing is needed.
- Verify subsequent clinical data and enrollment/timing for APEX, SUMMIT and PEAK; assess whether early response and safety findings hold in larger or later-stage studies.
- Monitor dilution and potential share supply from preferred-stock conversion, warrants, equity compensation and future capital raises.
- Confirm progress and timing for CGT4859 and the ErbB2 program, and review any future regulatory, licensing or partnership updates.